Dilation Capital Management LP Invests $5.11 Million in Henry Schein, Inc. $HSIC

Dilation Capital Management LP bought a new stake in Henry Schein, Inc. (NASDAQ:HSIC) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 76,920 shares of the company’s stock, valued at approximately $5,105,000. Henry Schein accounts for 2.5% of Dilation Capital Management LP’s investment portfolio, making the stock its 18th biggest holding. Dilation Capital Management LP owned approximately 0.06% of Henry Schein as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. CYBER HORNET ETFs LLC purchased a new position in Henry Schein during the second quarter valued at $25,000. MUFG Securities EMEA plc purchased a new position in Henry Schein during the 2nd quarter valued at about $27,000. ANTIPODES PARTNERS Ltd purchased a new position in Henry Schein during the 2nd quarter valued at about $43,000. Steph & Co. bought a new stake in Henry Schein during the second quarter worth about $44,000. Finally, CX Institutional grew its holdings in Henry Schein by 107.3% in the second quarter. CX Institutional now owns 651 shares of the company’s stock worth $48,000 after purchasing an additional 337 shares during the period. 96.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Wells Fargo & Company boosted their price target on Henry Schein from $70.00 to $76.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 5th. Mizuho set a $81.00 target price on Henry Schein and gave the stock a “neutral” rating in a report on Tuesday. Wall Street Zen upgraded Henry Schein from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Barrington Research set a $79.00 price target on Henry Schein and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Finally, Morgan Stanley raised their price objective on shares of Henry Schein from $55.00 to $58.00 and gave the company an “underweight” rating in a research note on Wednesday, November 5th. Five equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $76.69.

Henry Schein Trading Up 1.6%

Henry Schein stock opened at $78.94 on Thursday. Henry Schein, Inc. has a one year low of $60.56 and a one year high of $82.49. The business’s fifty day moving average is $75.64 and its 200 day moving average is $70.62. The stock has a market capitalization of $9.29 billion, a PE ratio of 24.98, a price-to-earnings-growth ratio of 2.31 and a beta of 0.88. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.40 and a quick ratio of 0.79.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, November 4th. The company reported $1.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.11. The business had revenue of $3.34 billion for the quarter, compared to analysts’ expectations of $3.28 billion. Henry Schein had a net margin of 3.02% and a return on equity of 14.76%. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. On average, sell-side analysts predict that Henry Schein, Inc. will post 4.74 EPS for the current year.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.